ArticleCurrent opinion in biomedical engineering2026
Design Considerations for Potent DNA-Platform-Based Cancer Vaccines.
Article in Current opinion in biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer vaccines have the potential to harness the strength of our immune system to fight cancer safely and effectively, but their potency relies on the presentation and tuned delivery of the vaccine's components. Different than other delivery platforms, DNA-based nanostructures are highly programmable architectures that allow for precise control of size, geometry, flexibility, and spatial organization of the scaffold and conjugated moieties. The modularity of DNA-based nanostructures enables the field to consider and program various determinants of vaccine potency including biodistribution, cargo protection, cellular uptake, and intracellular processing. Consequently, numerous design strategies have emerged using various DNA-based materials. Collectively, these developments have illustrated how slight alterations in structure notably impacts the directions and strengths of the resulting immunostimulatory responses against tumors. As the relationship between structure and immunomodulation becomes increasingly understood, the potential of DNA-based nanostructures to serve as precise and potent cancer vaccine delivery platforms will be further realized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.